Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
Cytokinetics (Nasdaq: CYTK) said MYQORZO® (aficamten) has launched commercially in Germany, the first European availability, for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA II–III). The company cited EU approval in February 2026 based on SEQUOIA-HCM Phase 3 results, including a 1.76 mL/kg/min pVO2 improvement vs 0.0 with placebo over 24 weeks.
How this was made
The 30-second read
Why it matters
The Germany launch is the first step in planned European rollouts, potentially increasing near-term demand visibility and reducing regulatory overhang for EU commercialization.
Market read
Commercial milestone (Germany first EU availability) following EU approval; supports a positive CYTK narrative but lacks quantitative revenue guidance.
What to watch
Commercial impact will depend on German prescribing uptake, center penetration, payer coverage/restrictions, and any label nuances versus the US/China approvals.
Background
MYQORZO (aficamten) is already approved in the U.S. (Dec 2025) and China, and the EU approval came in Feb 2026 based on SEQUOIA-HCM Phase 3 results published in NEJM.
Ticker impact
Cytokinetics announced first commercial European availability of MYQORZO (aficamten) in Germany after EU approval, expanding approved markets for its lead drug.
Near-term positive bias for CYTK as market access expands; magnitude likely moderate absent new financial guidance.
The news is a concrete commercialization milestone (first EU country availability) tied to an already-approved product, but the article provides no revenue, pricing, reimbursement, or launch-forecast numbers.
Market effects
Reinforces confidence in cardiac myosin inhibitor commercialization pathways in obstructive HCM and may lift sentiment toward similar cardiology specialty biopharma programs.
EU/ Germany market access expansion can improve perceived addressable market for MYQORZO versus US-only commercialization.
Adds to the multi-region approval footprint (US, China, EU), supporting a global scaling narrative for aficamten.
Counterpoint
A first-country EU launch may not materially change near-term fundamentals without details on pricing, reimbursement, and sales ramp assumptions.
Key entities
- companyCytokinetics, Incorporated
Announced first commercial European availability of MYQORZO in Germany for symptomatic oHCM.
- productMYQORZO (aficamten)
Allosteric, reversible cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy.
- clinical_trialSEQUOIA-HCM
Pivotal Phase 3 trial supporting EU approval with statistically significant improvement in peak oxygen uptake.
